N,N,2-Trimethylnicotinamid | 55314-17-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N,N,2-Trimethylnicotinamid
• 英文别名: 2,N,N-trimethyl-nicotinamide；2,N,N-trimethyl-nicotinic amide；N,N,2-trimethylnicotinamide；N,N,2-trimethylpyridine-3-carboxamide
• CAS: 55314-17-5
• 化学式: C₉H₁₂N₂O
• 分子量: 164.207
• InChiKey: XBVSRNYDOKRPLQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
  申请人：Honda Takahiro

  公开号：US20070149574A1

  公开（公告）日：2007-06-28

  A novel cyclic compound having a 4-pyridylalkylthio group having an (un)substituted amino group introduced therein or a salt thereof. They are useful as a medicine. The cyclic compound is a compound represented by the following formula (1), which is useful for the treatment of diseases in which angiogenesis participates. In the following formula (1), ring A represents a benzene ring or a 5- or 6-membered aromatic heterocycle optionally fused with a cycloalkane ring; B represents alkylene; R 1 and R 2 each represents H, (substituted) aryl, (substituted) heterocyclic group, etc.; R 3 and R 4 each represents H, (substituted) alkyl, (substituted) cycloalkyl, -Z-R 5 , etc.; R 5 represents (substituted) alkyl, (substituted) aryl, (substituted) heterocyclic group, etc.; X and Y each represents H, etc.; Z represents —CO—, —COO—, —CONR 6 —, —SO 2 —, etc.; R 6 represents H, etc.; p is 0, 1, or 2; and q is 0 or 1.

  一种具有4-吡啶基烷基硫基团的新型环状化合物，其中引入了（未）取代氨基或其盐。它们可用作药物。环状化合物是由以下式（1）表示的化合物，可用于治疗参与血管生成的疾病。在下式（1）中，环A表示苯环或5-或6-成员芳香杂环，可选择地与环烷环融合；B表示烷基；R1和R2各表示H，（取代）芳基，（取代）杂环基等；R3和R4各表示H，（取代）烷基，（取代）环烷基，-Z-R5等；R5表示（取代）烷基，（取代）芳基，（取代）杂环基等；X和Y各表示H等；Z表示-CO-，-COO-，-CONR6-，-SO2-等；R6表示H等；p为0、1或2；q为0或1。
• Novel Cyclic Compound Having Pyrimidinylalkylthio Group
  申请人：Tajima Hisashi

  公开号：US20090291951A1

  公开（公告）日：2009-11-26

  The present invention has its object to study synthesis of novel cyclic compounds having a pyrimidinylalkylthio group and to find pharmacological actions of the compounds. According to the present invention, a compound represented by the formula (1) or a salt thereof is provided. In the formula, the ring X represents: R 1 and R 2 independently represent a hydrogen atom, an alkyl group, an aryl group, an aromatic heterocyclic group or the like; R 3 represents a hydrogen atom, a halogen atom, a hydroxy group, an alkoxy group, an aryloxy group, an alkyl group, an aryl group, an amino group, an alkylamino group or the like; A 1 represents a sulfur atom or the like; and A 2 represents an alkylene group.

  本发明旨在研究具有嘧啶基烷基硫基团的新型环状化合物的合成，并找到这些化合物的药理作用。根据本发明，提供了由式（1）表示的化合物或其盐。其中，环X表示：R1和R2独立地表示氢原子、烷基、芳基、芳香杂环基或类似物；R3表示氢原子、卤原子、羟基、烷氧基、芳氧基、烷基、芳基、氨基、烷基氨基或类似物；A1表示硫原子或类似物；A2表示烷基链。
• Novel cyclic compound having quinolylalkylthio group
  申请人：Kawashima Kenji

  公开号：US20080021064A1

  公开（公告）日：2008-01-24

  The present invention relates to a synthesis study of novel cyclic compounds having a quinolylalkylthio group represented by the formula (1), and pharmacological actions of the compounds. In the formula, the ring X represents: which may have halogen and/or alkyl; R 1 and R 2 independently represent hydrogen, alkyl, cycloalkyl, aryl or a (non) aromatic heterocycle; R 3 represents qinolyl; A represents sulfur, sulfinyl or sulfonyl; and B represents alkylene.

  本发明涉及一种合成具有式（1）所表示的喹诺基烷基硫基的新型环状化合物的研究，以及所述化合物的药理作用。在该式中，环X代表：可能具有卤素和/或烷基；R1和R2独立地表示氢、烷基、环烷基、芳基或（非）芳香杂环；R3表示喹诺基；A表示硫、亚砜或磺酰基；B表示烷基。
• Heteroaryl sulfonamides and CCR2/CCR9
  申请人：Ungashe Solomon

  公开号：US20110118248A1

  公开（公告）日：2011-05-19

  Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.

  提供了一些化合物，可以作为CCR2受体的有效拮抗剂。动物实验表明，这些化合物对于治疗CCR2标志性疾病炎症很有用。这些化合物通常是芳基磺酰胺衍生物，并且可用于制药组合物、治疗CCR2介导疾病的方法以及作为CCR2拮抗剂鉴定试验的对照。
• Novel cyclic compound having pyrimidinylalkylthio group
  申请人：Tajima Hisashi

  公开号：US20110124646A1

  公开（公告）日：2011-05-26

  A method of treating a disease associated with angiogenesis by administering a therapeutically effective amount of a compound represented by the formula (1) or a salt thereof wherein the ring X represents R 1 and R 2 independently represent a hydrogen atom, an alkyl, an aryl or an aromatic heterocyclic; R 3 represents a hydrogen atom, a halogen atom, a hydroxy, an alkoxy, an aryloxy, an alkyl, an aryl, an amino, an alkylamino, a cycloalkylamino, an arylamino, an alkylcarbonylamino, an arylcarbonylamino, a mercapto, an alkylthio, an arylthio, an alkylsulfinyl or a nonaromatic heterocyclic; A 1 represents a sulfur atom, a sulfinyl or a sulfonyl; and A 2 represents an alkylene.

  通过给予化合物公式（1）或其盐的治疗有效量，治疗与血管生成相关的疾病的方法，其中环X代表R1和R2分别代表氢原子，烷基，芳基或芳香族杂环；R3代表氢原子，卤原子，羟基，烷氧基，芳氧基，烷基，芳基，氨基，烷基氨基，环烷基氨基，芳基氨基，烷基羰基氨基，芳基羰基氨基，巯基，烷硫基，芳硫基，烷基亚磺酰基或非芳香族杂环；A1代表硫原子，亚磺酰基或磺酰基；A2代表烷基。

表征谱图